The Politics of Pharma: Washington, States, and the Court's Impact on the Industry

Dublin, Sept. 23, 2013 (GLOBE NEWSWIRE) -- Research and Markets ( has announced the addition of the "The Politics of Pharma: Washington, States, and the Court's Impact on the Industry" report to their offering.

Politics have a greater direct effect on the pharmaceutical industry than almost any other in the US, and correspondingly, pharma makes considerable investments in election campaigns. The November elections kept the face of Washington the same, with the re-election of President Obama, Democratic control of the Senate and Republican control of the House. However, the outcome of the elections will still impact the industry in a variety of ways.

The Medical Device Excise Tax, a component of the 2010 health care reform legislation, survived a pre-election Congressional effort at repeal, but a coalition of House Republicans and Democrats from key states are looking to try again. Post-election, another bi-partisan congressional group is pushing for the FDA to impose stricter regulations on certain painkillers. Meanwhile, the Administration's prioritization of generics at the FDA remains controversial.

The budget impasse and resulting sequestration are election fall-outs that may impact the pharmaceutical industry in a number of ways: decreased vaccine sales, reduced research funding and potential cuts at the FDA that could dramatically raise time to market. Medicare reform also looms out as an issue un-resolved in November, with the possibility of playing a role in the mid-term elections

The report, The Politics of Pharma was written to provide companies with an update and future outlook of how the political atmosphere within the United States will impact the pharmaceutical industry in both the near and long term. This report should be used by both large and small organizations alike, as well as branded and generics manufacturers.

Key Reasons to Purchase

  • Understand the current pharmaceutical related issues before the Supreme Court
  • Assess the impact of the November elections on the political issues that affect pharma now and in the future
  • Evaluate where pharmaceutical companies should turn their political focus
  • Analyze why state politics are increasingly important to pharmaceutical companies and the impact they could have on future revenues
  • Examine the potential impact from the current budget impasse
  • Benefit from accessing CBR's view on the outlook for the pharmaceutical industry as a result of the political climate in the United States
  • Key Topics Covered:

Executive Summary

Chapter 1: November Election Results

  • Pharma's investment in the elections
  • Election results
  • Medical device tax
  • Congressional spotlight on painkillers
  • The FDA

Chapter 2: Health Care Reform

  • Implementation
  • The Sunshine Act
  • Meaningful use debate

Chapter 3: State Politics

  • State Health Care Exchanges
  • Biosimilar substitution

Chapter 4: The Courts

  • Pay-for-delay
  • Generics liability
  • Reform
  • Off-label use

Chapter 5: The Political Outlook

  • Impact of the budget impasse
  • Medicare
  • Indian trade issues
  • The CBR View


For more information visit

Research and Markets
Laura Wood, Senior Manager.
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Source:Research and Markets